Amrubicin Hydrochloride

DRUG3 trials

Sponsors

Japan Multinational Trial Organization, Sumitomo Pharma Co., Ltd., Sumitomo Pharma (Suzhou) Co., Ltd.

Conditions

Lung CancerSmall-cell Lung Cancer

Phase 1

Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer

CompletedNCT00132054

Japan Multinational Trial OrganizationLung Cancer

Start: 2004-05-31End: 2008-11-30Target: 30Updated: 2013-05-30

Phase 3

Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

TerminatedNCT00286169

Sumitomo Pharma Co., Ltd.Small-cell Lung Cancer

Start: 2006-04-30Target: 130Updated: 2022-04-12

Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer

CompletedNCT00660504

Sumitomo Pharma (Suzhou) Co., Ltd.Lung Cancer

Start: 2008-04-30End: 2012-08-31Updated: 2014-07-18

Related Papers

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.

2016-04-0930 citations